PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
BackgroundMetastatic gastric cancer (MGC) patients with progression on first-line treatment still have poor outcomes on chemotherapy. The KEYNOTE-061 study demonstrated that pembrolizumab, a PD-1inhibitor, was not better than paclitaxel as second-line therapy for MGC. Herein, we explored the efficac...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2023-05-01
|
| Colecção: | Frontiers in Immunology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1136437/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|